Gespräche der Bundesregierung mit den Unternehmen Boehringer Ingelheim und Eli Lilly seit Mai 2025

This procedure concerns written questions posed to the German federal government regarding discussions held with pharmaceutical companies Boehringer Ingelheim and Eli Lilly since May 2025. It seeks information on the nature and outcomes of these high-level meetings, potentially impacting public health policy and pharmaceutical regulation within Germany.